NSPR Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Stats
Šios dienos apimtis	10 238.00
Vidutinė apimtis	34 706.00
Rinkos kapitalizacija	46.80M
EPS	$0 ( 2024-04-04 )
Kita pelno data	( $-0.150 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.44
ATR14	$0.0220 (1.10%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-23	Kester Thomas J	Buy	29 032	Common Stock
2024-01-23	Kester Thomas J	Buy	11 098	Options to purchase common stock (right to buy)
2024-01-23	Verta Patrick	Buy	85 720	Common Stock
2024-01-23	Verta Patrick	Buy	32 768	Options to purchase common stock (right to buy)
2024-01-23	Gleason Shane Thomas	Buy	238 625	Common Stock

INSIDER POWER
98.06
Last 99 transactions
Buy: 7 620 190 \| Sell: 72 371

InspireMD Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

InspireMD Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$6.21M
Bruto pelnas:	$1.81M (29.12 %)
EPS:	$-0.820

FY	2023
Pajamos:	$6.21M
Bruto pelnas:	$1.81M (29.12 %)
EPS:	$-0.820

FY	2022
Pajamos:	$5.17M
Bruto pelnas:	$1.12M (21.60 %)
EPS:	$-2.35

FY	2021
Pajamos:	$4.50M
Bruto pelnas:	$754 000 (16.77 %)
EPS:	$-2.03

Financial Reports:

No articles found.

InspireMD Inc

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.